CABALETTA BIO, INC. Stock Split Ratio
CABALETTA BIO, INC. (CABA) reported Stock Split Ratio of 67.00% for the 0-month period ending 2019-10-16, per its 10-K filed 2021-03-16.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2021-03-16
- 2019-10-16: Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month 67.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month |
|---|---|
| 2019-10-16 | 67.00% 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |